Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(BI) 1381.1 / REFMAL 473An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumours Hirte, Dr HalOpen to recruitmentNCT02952248
(CCTG) IND.214A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid TumoursHotte, Dr SebastienOpen to recruitmentNCT02285816
(CCTG) IND.228A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare TumoursHirte, Dr HalOpen to recruitmentNCT02879162
(CCTG) IND.235 / CRI-CCTG-0001 / NIMBLeA Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based AssayHirte, Dr HalOpen to recruitmentNCT03461952
(Fusion) FPX-01-01A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid TumoursJuergens, Dr RosalynOpen to recruitmentNCT03746431
Download PDF